| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.UROLOGY.2015.11.006 |
| P698 | PubMed publication ID | 26616095 |
| P50 | author | Martin Kathrins | Q52883934 |
| Karen M Doersch | Q55754979 | ||
| Craig Niederberger | Q67190202 | ||
| Lane Allen | Q98119760 | ||
| P2093 | author name string | Tony Nimeh | |
| Arturo Canto | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860749 |
| Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only | Q34003029 | ||
| Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. | Q34066081 | ||
| Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline | Q34119261 | ||
| Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis | Q34486599 | ||
| Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial | Q34622506 | ||
| Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial | Q34732234 | ||
| Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia | Q35009627 | ||
| The role of estrogens and estrogen receptors in normal prostate growth and disease | Q36488068 | ||
| Levels of evidence ratings in the urological literature: an assessment of interobserver agreement | Q37678637 | ||
| Rating the quality of evidence and the strength of recommendations using GRADE. | Q37851039 | ||
| Is testosterone a friend or a foe of the prostate? | Q37860408 | ||
| A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review | Q38139618 | ||
| Benign prostatic hyperplasia: a new metabolic disease? | Q38181426 | ||
| Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial | Q38402163 | ||
| Testosterone supplementation does not worsen lower urinary tract symptoms. | Q39402891 | ||
| Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials | Q39738952 | ||
| Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia | Q39939082 | ||
| Prevalence of symptomatic androgen deficiency in men. | Q40183474 | ||
| A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism | Q42687589 | ||
| A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months | Q42792854 | ||
| Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients | Q42925108 | ||
| Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study | Q42934081 | ||
| Sex steroid receptors in male human bladder: expression and biological function | Q43088933 | ||
| Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study | Q43198484 | ||
| Effects of androgen deficiency and replacement on prostate zonal volumes | Q43585997 | ||
| Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume | Q43923479 | ||
| Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome | Q44181120 | ||
| A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function | Q44339663 | ||
| Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study | Q44427447 | ||
| AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function | Q44467064 | ||
| Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status | Q44514741 | ||
| Effects of different sex hormones on male rabbit urodynamics: an experimental study | Q44653507 | ||
| Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss | Q44725281 | ||
| Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. | Q44883216 | ||
| Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome | Q45267669 | ||
| Testosterone changes bladder and kidney structure in juvenile male rats | Q46085486 | ||
| Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study | Q46124632 | ||
| Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. | Q46163361 | ||
| The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism | Q46343590 | ||
| Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations | Q46388553 | ||
| Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study | Q46526834 | ||
| Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial | Q46630278 | ||
| Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life | Q48080535 | ||
| Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. | Q51013519 | ||
| Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. | Q51312023 | ||
| Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. | Q53162066 | ||
| Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. | Q53216481 | ||
| A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate | Q58290117 | ||
| Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls | Q71624041 | ||
| Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels | Q74095781 | ||
| Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years | Q78196764 | ||
| An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey | Q80345155 | ||
| Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function | Q80407085 | ||
| Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men | Q83862092 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 22-32 | |
| P577 | publication date | 2015-11-23 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review | |
| P478 | volume | 88 |
| Q61443073 | Factors Associated with Bothersome Lower Urinary Tract Symptoms in Middle-Aged Men Receiving Health Checkup |
| Q58555982 | Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms |
| Q38750063 | Male hormonal contraception: hope and promise |
| Q92044445 | Systemic Comorbidity Burden Using the ACTIONS Phenotype Predicts Urologic Medication Discontinuation Following Transurethral Resection of the Prostate |
| Q92543189 | Testosterone Management in Aging Males: Surveying Clinical Practices of Urologists and Endocrinologists in Israel |
| Q39412090 | Testosterone decreases urinary bladder smooth muscle excitability via novel signaling mechanism involving direct activation of the BK channels |
| Q28068397 | Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? |
| Q39607039 | Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. |
| Q39406932 | The landscape of systematic reviews in urology (1998 to 2015): an assessment of methodological quality. |
Search more.